MX2009002919A - Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos. - Google Patents

Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos.

Info

Publication number
MX2009002919A
MX2009002919A MX2009002919A MX2009002919A MX2009002919A MX 2009002919 A MX2009002919 A MX 2009002919A MX 2009002919 A MX2009002919 A MX 2009002919A MX 2009002919 A MX2009002919 A MX 2009002919A MX 2009002919 A MX2009002919 A MX 2009002919A
Authority
MX
Mexico
Prior art keywords
azetidone
azetidine
disorders
treating pain
lipid metabolism
Prior art date
Application number
MX2009002919A
Other languages
English (en)
Inventor
Brian Mckittrick
Duane A Burnett
Elizabeth M Smith
Chad E Knutson
Chad E Bennett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009002919A publication Critical patent/MX2009002919A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Abstract

Se describen compuestos de fórmula (ver fórmula I) en los cuales Z1 es -CH2- o -C(O)-, R4 y R5 son cadenas de carbono (y opcionalmente, juntos, pueden formar un puente C2), u y v son en forma independiente un número entero de 0-3 tal que la suma es desde 3 hasta 5, y R2 es heteroarilo, y R1 y R3 son como se define aquí; además, se describen métodos de tratamiento del dolor usando un compuesto de fórmula I.
MX2009002919A 2006-09-15 2007-09-13 Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos. MX2009002919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84480906P 2006-09-15 2006-09-15
PCT/US2007/019901 WO2008033447A1 (en) 2006-09-15 2007-09-13 Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism

Publications (1)

Publication Number Publication Date
MX2009002919A true MX2009002919A (es) 2009-04-01

Family

ID=39055043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002919A MX2009002919A (es) 2006-09-15 2007-09-13 Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos.

Country Status (9)

Country Link
US (1) US20080070888A1 (es)
EP (1) EP2066316A1 (es)
JP (1) JP2010503673A (es)
CN (1) CN101534818A (es)
AR (1) AR062789A1 (es)
CA (1) CA2663947A1 (es)
MX (1) MX2009002919A (es)
TW (1) TW200820969A (es)
WO (1) WO2008033447A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528746A (zh) * 2006-09-15 2009-09-09 先灵公司 治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
CA2663504A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
US7638526B2 (en) * 2006-09-15 2009-12-29 Schering Corporation Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
WO2008033464A2 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
EP2091534A1 (en) * 2006-09-15 2009-08-26 Schering Corporation Azetidinone derivatives and methods of use thereof
EP2286224A4 (en) * 2008-05-05 2012-04-25 Univ Winthrop Hospital METHOD FOR IMPROVING THE CARDIOVASCULAR RISK PROFILE OF COX-INHIBITORS
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
EP2671582B1 (en) 2011-02-01 2016-07-13 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
US9540366B2 (en) 2012-07-31 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic compound
CN104603104B (zh) * 2012-09-05 2016-12-07 浙江海正药业股份有限公司 氮杂环丁烷酮化合物的晶型及其制备方法
KR20230152818A (ko) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
RU2015139732A (ru) 2013-03-15 2017-04-24 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
WO2015140132A1 (en) * 2014-03-17 2015-09-24 Remynd Nv 2,7-diazaspiro[3.5]nonane compounds
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
EP3860571A4 (en) 2018-10-03 2022-06-29 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
AU2020221239A1 (en) 2019-02-12 2021-09-16 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
WO2023122662A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US6313299B1 (en) * 1997-06-26 2001-11-06 Dong Wha Pharmaceutical Industrial Co., Ltd. Quinolone carboxylic acid derivatives
NZ506793A (en) * 1998-05-26 2003-03-28 Warner Lambert Co Conformationally constrained amino acid compounds and their use for treating epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders
DE60330456D1 (de) * 2002-07-05 2010-01-21 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung

Also Published As

Publication number Publication date
CN101534818A (zh) 2009-09-16
JP2010503673A (ja) 2010-02-04
CA2663947A1 (en) 2008-03-20
TW200820969A (en) 2008-05-16
EP2066316A1 (en) 2009-06-10
US20080070888A1 (en) 2008-03-20
AR062789A1 (es) 2008-12-03
WO2008033447A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
MX2009002919A (es) Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos.
MX2009002922A (es) Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
TW200740752A (en) 4-Biarylyl-1-phenylazetidin-2-ones
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
UA99624C2 (uk) Сульфонаміди як trpm8-модулятори
WO2009049180A3 (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
RS20050469A (en) Pyrrolopyrimidine derivatives
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
MXPA05010433A (es) Derivados de pirrolidina y procedimiento para prepararlos.
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
TW200719889A (en) Amino acid derivatives
MXPA05010020A (es) Derivados de oxamida.
HK1141019A1 (en) Carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
TW200407133A (en) Novel PPARα and PPARγ agonists
EP2077719A4 (en) BETA-SECRETASE PIPERIDINE AND PYRROLIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AU2003291134A1 (en) Use of diamide derivatives for inhibiting chronic tissue transplant rejection
PL1819704T3 (pl) Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej
MXPA06000269A (es) Tiofenilaminoimidazolinas.
EA200600316A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗУЕМЫЕ В НЕМ ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal